Objective: MiniMed™ 780G system use has improved glycemic control in clinical trials1,2 and real-world data analyses3. This study evaluated real-word glycemic outcomes before and 6 months after AHCL initiation by individuals with T1D living in Chile.

Methods: Data from 37 MiniMed™ 780G users (aged 5-76 years, mean±SD of 29.3±19.3 years) at 12 centers throughout Chile were prospectively collected and analyzed. Mean glucose management indicator (GMI) , sensor and system use, and time spent at SG ranges including target SG range (TIR, 70-180mg/dL) were determined using 14 days of SG data at baseline and 2, 14, 28, 90 and 180 days post-AHCL initiation.

Results: Overall, ≥95% of time was spent in AHCL (Figure 1) and GMI was <7% throughout the study. TIR increased from 68.9% to 79.5% in 7 former MiniMed™ 640G users and from 75.3% to 78.1% in 30 former MiniMed™ 670G users. The percentage of users achieving TIR >70% and GMI <7.0% increased from 63.6% to 86.5% and from 70.3% to 82.4% by 180 days post-AHCL initiation, respectively.

Conclusion: MiniMed™ 780G use in Chile allowed most to increase TIR within 2 weeks, an important outcome that was sustained over 6 months.


M.Castro: Employee; Medtronic. C.Carrasco bonilla: Employee; Medtronic. J.C.Leon macedo: Employee; Medtronic. M.Gutierrez: Employee; Medtronic. Z.C.Valera lopez: Employee; Medtronic. A.Daghero: Employee; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.